Axsome Therapeutics, Inc. $AXSM Shares Purchased by Citigroup Inc.

Citigroup Inc. boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 67.1% in the 3rd quarter, Holdings Channel reports. The fund owned 142,013 shares of the company’s stock after acquiring an additional 57,002 shares during the quarter. Citigroup Inc.’s holdings in Axsome Therapeutics were worth $17,247,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new position in Axsome Therapeutics in the 2nd quarter worth approximately $48,889,000. Adage Capital Partners GP L.L.C. lifted its position in Axsome Therapeutics by 831.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after buying an additional 399,000 shares in the last quarter. Hood River Capital Management LLC acquired a new position in Axsome Therapeutics during the second quarter worth $38,740,000. Vanguard Group Inc. boosted its stake in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after buying an additional 235,626 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Axsome Therapeutics by 41.1% in the 2nd quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock valued at $78,650,000 after buying an additional 219,527 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on AXSM shares. HC Wainwright raised their target price on Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Mizuho set a $230.00 target price on shares of Axsome Therapeutics in a research note on Thursday, February 19th. Truist Financial set a $200.00 target price on shares of Axsome Therapeutics in a report on Monday. Robert W. Baird set a $209.00 price target on shares of Axsome Therapeutics in a report on Tuesday, January 13th. Finally, Guggenheim lifted their price target on shares of Axsome Therapeutics from $205.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday. Seventeen research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $216.12.

Insider Activity

In related news, COO Mark L. Jacobson sold 35,378 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.88, for a total transaction of $5,726,990.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $171.28, for a total value of $13,480,249.84. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,238,183.12. This represents a 91.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 369,252 shares of company stock worth $61,145,545 in the last quarter. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $163.89 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. The firm has a market cap of $8.38 billion, a P/E ratio of -44.41 and a beta of 0.40. The firm’s 50 day moving average price is $175.78 and its 200-day moving average price is $146.07. Axsome Therapeutics, Inc. has a one year low of $86.99 and a one year high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The company had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. The company’s revenue was up 65.0% on a year-over-year basis. As a group, equities research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.